September 27 - 30, 2023 Athens
![]() |
![]() |
![]() |
![]() |
1-P | The bone marrow stroma influences extrinsic apoptotic signaling and results in resistance to BCMA CAR-T cell induced cell death | James Ackley | ![]() |
![]() |
|||
2-P | Impact of Bridging Therapy (BT) on outcome of Relapsed Refractory Multiple Myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world Experience from the U.S. Myeloma CAR T Consortium | Larry Anderson | ![]() |
![]() |
|||
7-P | Prognostic Impact of Corticosteroid and Tocilizumab Use on the Efficacy of Chimeric Antigen Receptor T-cell Therapy for Relapsed/Refractory Multiple Myeloma | Bruno Costa | ![]() |
![]() |
|||
8-NSP | Co-designing a pilot patient support program (PSP) for a multiple myeloma (MM) therapy prior to listing on the Pharmaceutical Benefits Scheme | Emma-Jane Furphy | ![]() |
![]() |
|||
9-P | Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma | Luise Fischer | ![]() |
![]() |
|||
10-P | Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel) | Samantha Sawh | ![]() |
![]() |
|||
11-P | Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies | Jan Frenking | ![]() |
![]() |
|||
12-NSP | Multiple Myeloma and Disparate Populations: The Path Forward | Rebecca Lu | ![]() |
![]() |
|||
13-NSP | Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS) | Anastasiia Savchenko | ![]() |
![]() |
|||
13-P | Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy. | Issam Hamadeh | ![]() |
![]() |
|||
15-P | A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma | Simon Harrison | ![]() |
![]() |
|||
16-P | DISPARITIES IN ACCESS AND PRACTICE PATTERNS OF BCMA-DIRECTED T-CELL ENGAGER (TCE) THERAPIES IN MULTIPLE MYELOMA: A GLOBAL PERSPECTIVE | Hamza Hassan | ![]() |
![]() |
|||
17-P | Real-World Efficacy of CAR T-Cell Therapies: A HealthTree Cure Hubs Study of Multiple Myeloma Patients | Jay Hydren | ![]() |
![]() |
|||
24-P | Early outcomes and therapy modification strategies in Multiple Myeloma patients treated with teclistamab, CD3XBCMA BITE; a single center experience. | Swarup Kumar | ![]() |
![]() |
|||
27-P | Hotspot mutations in BCMA extracellular domain lead to differential susceptibility to anti-BCMA targeted immunotherapies | Holly Lee | ![]() |
![]() |
|||
31-P | Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-classexposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy | Samantha Sawh | ![]() |
![]() |
|||
32-P | Ide-cel versus standard regimens in patients with triple-classexposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population | Michael Rowlands | ![]() |
![]() |
|||
36-P | REAL WORLD SINGLE CENTER EXPERIENCE OF LONG-TERM TOXICITIES WITH ANTI-BCMA CAR T-CELL THERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA | Patrick Costello | ![]() |
![]() |
|||
38-P | Impact of Absolute Lymphocyte Count at pre-apheresis and pre-lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM) | Noriko Nishimura | ![]() |
![]() |
|||
39-P | Vitamin D Deficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma | Noriko Nishimura | ![]() |
![]() |
|||
40-P | Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis | Michael Rowlands | ![]() |
![]() |
|||
43-P | Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Early results from an IIT | Sridevi Rajeeve | ![]() |
![]() |
|||
47-P | TRIAL IN PROGRESS: AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF IGM-2644 IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) | Kevin Hart | ![]() |
![]() |
|||
49-P | Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience | Surbhi Sidana | ![]() |
![]() |
|||
53-P | Idecabtagene vicleucel retreatment response was characterized by poor activation, impaired cellular expansion, and limited cytolytic activity of chimeric antigen receptor T cells | Stephanie Wolfe | ![]() |
![]() |
|||
62-P | Real-world evidence of bisphosphonates and denosumab for Multiple Myeloma | Nieves Lopez-Muñoz | ![]() |
![]() |
|||
64-P | COMPARISON BETWEEN MRI AND PET/CT IN THE DIAGNOSIS OF PLASMACYTOMAS AND THEIR CLINICAL AND RADIOLOGICLA FOLLOW-UP | Isabel Vicuna | ![]() |
![]() |
|||
69-P | Liquid biopsy monitoring is more sensitive than alternative techniques in extramedullary multiple myeloma | Nicholas Bingham | ![]() |
![]() |
|||
70-P | Failure to Clear Circulating Tumor Cells After One Week of Daratumumab, Bortezomib and Dexamethasone is Associated with a Reduced Progression-Free Survival for Myeloma Patients | Christian Bryant | ![]() |
![]() |
|||
72-P | Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing | Jay Hydren | ![]() |
![]() |
|||
73-P | Modelling multiple myeloma using best clinical response to treatment to predict overall survival | Adam Irving | ![]() |
![]() |
|||
74-P | Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients | Joannes Jacobs | ![]() |
![]() |
|||
77-P | High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping | Sherif Louis | ![]() |
![]() |
|||
78-P | MRDeep Study: Measurable Residual Disease rates in patients with Multiple Myeloma who achieved complete response in 2nd or 3rd lines of treatment. | Rita Jaime | ![]() |
![]() |
|||
79-P | Impact of treatment effect on measurable residual disease (MRD) and progression-free survival (PFS): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM) | Bruno Paiva | ![]() |
![]() |
|||
82-P | Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study | Anne-Marie Rasmussen | ![]() |
![]() |
|||
84-P | Use of Peripheral Blood for MRD Assessment During Maintenance Therapy: UTSW Experience | Aishwarya Sannareddy | ![]() |
![]() |
|||
86-P | Patient and Haematologist Perspectives of Minimal Residual Disease Testing in Myeloma | Silène ten Seldam | ![]() |
![]() |
|||
89-P | Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma | Theresia Akhlaghi | ![]() |
![]() |
|||
90-P | CLINICAL CHARACTERISTICS AND RISK OF PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE: LONG-TERM EXPERIENCE IN A SINGLE TERTIARY HOSPITAL. | Elena Alejo Alonso | ![]() |
![]() |
|||
92-P | High Serum Free Light Chains levels in African Ancestry population screened for Monoclonal Gammopathy: implication for definition of FLC Reference Range Accounting for Renal Function and Race | Luca Bertamini | ![]() |
![]() |
|||
95-P | Evolving M-spike and Risk of Progression in Smoldering Multiple Myeloma | Malin Hultcrantz | ![]() |
![]() |
|||
96-P | Real world evidence of suboptimal humoral and cellular immune response to vaccination in ostensibly asymptomatic patients with precursor stage of multiple myeloma | Yoshinobu Konishi | ![]() |
![]() |
|||
99-P | Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | OMAR NADEEM | ![]() |
![]() |
|||
101-P | Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM | Romanos Sklavenitis-Pistofidis | ![]() |
![]() |
|||
102-P | Thrombotic Significance in Plasma Cell Disorders: Do associated clonal hematopoiesis of indeterminate potential (CHIP) mutations increase the risk? | ritika vankina | ![]() |
![]() |
|||
107-P | The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings | Jelena Bila | ![]() |
![]() |
|||
108-P | Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. CARINAE Study. | Miriam Gonzalez | ![]() |
![]() |
|||
110-P | Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: Final overall survival analysis from the TOURMALINE-MM4 study | Meletios Dimopoulos | ![]() |
![]() |
|||
111-P | Overall survival trends in young ( 55 years) transplant-inaccessible multiple myeloma patients treated at a safety net hospital system | Sharlene Dong | ![]() |
![]() |
|||
112-P | Determining the impact of multimorbidity in older patients initiating treatment for newly-diagnosed multiple myeloma using artificial intelligence/machine learning methods | Nathanael Fillmore | ![]() |
![]() |
|||
114-P | In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: Updated subgroup analysis from the fully accrued US MM-6 study | Saulius Girnius | ![]() |
![]() |
|||
119-P | The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy | Jihyun Kwon | ![]() |
![]() |
|||
120-P | Impact of exclusion from clinical trials in non-candidate transplant patients with newly diagnosed multiple myeloma | Luis Gerardo Rodríguez-Lobato | ![]() |
![]() |
|||
121-P | Real World Outcomes of Undocumented Multiple Myeloma Patients: A Safety Net Hospital Experience | Aishwarya Sannareddy | ![]() |
![]() |
|||
124-P | Therapeutic efficacy of ixazomib-based regimen in frail patients with newly diagnosed multiple myeloma based on the dynamic assessment of frailty | HUA XUE | ![]() |
![]() |
|||
127-P | Bone marrow plasmacytosis 5 at time of autologous transplant influences survival outcomes in patients with standard risk cytogenetics | Louis Williams | ![]() |
![]() |
|||
128-P | DARATUMUMAB- VTD VS VTD. PERI-TRANSPLANT EVALUATION. | BELEN BALLINA MARTIN | ![]() |
![]() |
|||
131-P | Daratumumab (dara) as maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): Results of a phase 2 study | Azra Borogovac | ![]() |
![]() |
|||
135-P | Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202) | Hyungwoo Cho | ![]() |
![]() |
|||
136-P | Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma | Qi Zhang | ![]() |
![]() |
|||
140-P | MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY | Amanda Ferreira | ![]() |
![]() |
|||
141-P | Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients | Nisha Joseph | ![]() |
![]() |
|||
142-P | Stem cell collection after isatuximab or elotuzumab plus lenalidomide, bortezomib and dexamethasone in transplant-eligible multiple myeloma: single center data from the GMMG-HD6 and -HD7 trials | Joseph Kauer | ![]() |
![]() |
|||
143-P | Treatment access among Black and White older adults with multiple myeloma: A SEER-Medicare analysis | Matthew LeBlanc | ![]() |
![]() |
|||
157-P | How public policies have improved the overall survival of transplant eligible newly diagnosed multiple myeloma patients in the Chilean public health system | Camila Peña | ![]() |
![]() |
|||
158-P | EXPERIENCE AT SON ESPASES UNIVERSITARY HOSPITAL WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (D-VRd) AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA | Lola Piquer Monsonis | ![]() |
![]() |
|||
162-P | Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma | Gunjan Shah | ![]() |
![]() |
|||
166-P | Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) vs Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma | Carlyn Rose Tan | ![]() |
![]() |
|||
169-P | CLINICAL FEATURES AND OUTCOME PATTERNS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE CANDIDATE FOR TRANSPLANT: A SINGLE CENTER EXPERIENCE IN PARAGUAY | Alana von Glasenapp | ![]() |
![]() |
|||
178-P | Evolution of the Multiple Myeloma Treatment Landscape in Portugal: a 5-year longitudinal analysis of treatment patterns in nationwide clinical practice | Rui Bergantim | ![]() |
![]() |
|||
179-P | Altered Lipid Metabolism in IMiD/CELMoD Resistant Multiple Myeloma Confers Novel and Targetable Vulnerabilities | Sarah Bird | ![]() |
![]() |
|||
182-P | Natural killer cells are active against myeloma cells with loss of tumor suppressor genes | Olga Dashevsky | ![]() |
![]() |
|||
187-P | Therapeutically Targeting 19S Proteasome-associated Subunit PSMD1/Rpn2 in Multiple Myeloma | Ting Du | ![]() |
![]() |
|||
190-P | Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma | Kris Frese | ![]() |
![]() |
|||
191-P | Acquisition of venetoclax resistance is characterized by higher expression of anti-apoptotic regulators, less mitochondrial priming, and broader resistance to anti-MM agents. | Mariateresa Fulciniti | ![]() |
![]() |
|||
195-P | Loss of GABARAP mediates resistance to immunogenic chemotherapy by altering protein trafficking of calreticulin on the cell surface | Annamaria Gulla | ![]() |
![]() |
|||
197-P | Tissue factor as a new target for CAR-NK cell immunotherapy of multiple myeloma and triple-negative breast cancer | Zhiwei Hu | ![]() |
![]() |
|||
200-P | MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism | Suzanne Lentzsch | ![]() |
![]() |
|||
203-P | Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The iinnovate clinical development program | Hira Mian | ![]() |
![]() |
|||
205-P | Heme promotes venetoclax resistance in multiple myeloma | Remya Nair | ![]() |
![]() |
|||
211-P | Antiviral treatment improves outcome for individuals with multiple myeloma and other monoclonal gammopathies associated with Hepatitis B or C viruses. | Alba Rodriguez | ![]() |
![]() |
|||
212-P | THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA | Alba Rodríguez-García | ![]() |
![]() |
|||
213-P | COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Courtney Follit | ![]() |
![]() |
|||
214-P | A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma | Michael Rosenzweig | ![]() |
![]() |
|||
219-P | Investigating the Proteasome Stress Response as a Potential Therapeutic Target in Multiple Myeloma | Cameron Van Cleave | ![]() |
![]() |
|||
220-P | Discovery of tumor-reactive T cell receptors by functional single cell interaction analyses in patients with newly diagnosed multiple myeloma | Tim Robin Wagner | ![]() |
![]() |
|||
225-P | Uninvolved hypogammaglobulinemia was not a predictor of the infection risk in anti-CD38 chemotherapy | Firas Al-Kaisi | ![]() |
![]() |
|||
229-P | Exposure-Response Analysis of Venetoclax in Combination with Carfilzomib and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients | Mohamed Badawi | ![]() |
![]() |
|||
230-P | Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma: final overall survival analysis of the phase 2 MM-014 study | Stephanie Wolfe | ![]() |
![]() |
|||
231-P | ABBV-383, a BCMA-CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: A Multicenter, Phase 1b Dose Optimization Study With Step-up Dosing | Muhamed Baljevic | ![]() |
![]() |
|||
232-P | Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment | Steve Mitchell | ![]() |
![]() |
|||
233-P | Physician perspectives regarding conventional marrow testing and MRD assessments to guide decision-making in myeloma | Rahul Banerjee | ![]() |
![]() |
|||
234-P | DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REAL WORLD EVIDENCE EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM) | Josip Batinic | ![]() |
![]() |
|||
235-P | Clinical and sociodemographic characterization of multiple myeloma patients with symptomatic relapse and/or refractory disease under treatment in Portugal: an observational, multicenter study | Diogo Morais | ![]() |
![]() |
|||
237-P | Bendamustine (B) is associated with low response rates in heavily pretreated relapsed refractory multiple myeloma (RRMM) | Natalie Callander | ![]() |
![]() |
|||
241-P | African American Relapsed/Refractory Multiple Myeloma patients have a Progression Free Survival benefit with selinexor treatment in the STORM study | Craig Cole | ![]() |
![]() |
|||
255-P | Efficacy of a Second Autologous Stem Cell Transplant for Multiple Myeloma and Correlation with Response to Initial Transplant: A Single-Center Experience | Barry Paul | ![]() |
![]() |
|||
258-P | CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REAL WORLD EVIDENCE EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM) | Davor Galusic | ![]() |
![]() |
|||
264-P | A Phase 1b Study of Isatuximab and Bendamustine for Triple-Class Refractory Multiple Myeloma | Scott Goldsmith | ![]() |
![]() |
|||
273-P | Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience | Masaki Iino | ![]() |
![]() |
|||
276-P | Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy | Mary Baugh | ![]() |
![]() |
|||
277-P | Venetoclax Versus Bortezomib, in Combination with Daratumumab and Dexamethasone, in Patients With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma | Amanda Ward | ![]() |
![]() |
|||
278-P | Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States | Mary Baugh/MedThinkSciCom | ![]() |
![]() |
|||
279-P | Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Real world Patients with Relapsed/Refractory Multiple Myeloma: KMM2004 study | Ho-Jin Shin | ![]() |
![]() |
|||
280-P | A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM) | swarup kumar | ![]() |
![]() |
|||
287-P | Isatuximab Plus Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma in Real Life Context in France: IMAGE Subgroup Analysis Based on Subgroups of Interest | Kirsty Lee | ![]() |
![]() |
|||
289-P | The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy. | Eric Wenlong Li | ![]() |
![]() |
|||
291-P | Outcomes of Third-Line Therapy in Multiple Myeloma Patients: a Report from the Canadian Myeloma Research Group (CMRG) | Martha Louzada | ![]() |
![]() |
|||
293-P | Real-World Treatment Patterns and Outcomes in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey | Emily Luke | ![]() |
![]() |
|||
296-P | LIGHTHOUSE: MELFLUFEN, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO AN IMID AND A PROTEASOME INHIBITOR OR WITH =3 PRIOR LINES OF THERAPY | Megan Ruzomberka | ![]() |
![]() |
|||
302-P | ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)FINAL EFFICACY AND SAFETY RESULTS | Megan Ruzomberka | ![]() |
![]() |
|||
304-P | TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA: EFICACY OF THE NEW IMMUNOTHERAPIES AND NEW UNMET MEDICAL NEED | Borja Puertas | ![]() |
![]() |
|||
305-P | DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS | Michael Checkoway | ![]() |
![]() |
|||
306-P | Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) | Mackenzie Baciuska | ![]() |
![]() |
|||
308-P | Superiority of daratumumab plus lenalidomide and dexamethasone in first and second relapse in multiple myeloma patients: a real-world single center retrospective analysis | Michel Delforge | ![]() |
![]() |
|||
314-P | Bendamustine Salvage for Relapsed Refractory Multiple Myeloma: A retrospective analysis of outcomes in heavily pretreated patients. | Aakanksha Singh | ![]() |
![]() |
|||
316-P | NK cell kinetics predict outcome in the multiple treated with elotuzumab, lenalidomide plus dexamethasone (ERd): a subanalysis in Japanese multicenter observation for once monthly ERd study. | Kazuhito Suzuki | ![]() |
![]() |
|||
323-P | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone Versus Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma | Steve Mitchell | ![]() |
![]() |
|||
329-P | A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma | Andrew Yee | ![]() |
![]() |
|||
335-P | Small nucleotide, copy number and structural variants cooperate to hijack driver genes in extramedullary progression of myeloma | Nicholas Bingham | ![]() |
![]() |
|||
337-P | The germinal center origin and progression of MM is captured by 83 Vk*MYC MM transplantable lines that share overlapping genomic diversity with human disease | Marta Chesi | ![]() |
![]() |
|||
342-P | Genomic Profiling of Treated High-Risk Smoldering Multiple Myeloma | Benjamin Diamond | ![]() |
![]() |
|||
348-P | ADAR1-regulated cytoplasmic dsRNA-immune sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma | Mun Yee Koh | ![]() |
![]() |
|||
349-P | A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience | Swarup Kumar | ![]() |
![]() |
|||
351-P | Are genomic lesions of Cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)? | Lisa Leypoldt | ![]() |
![]() |
|||
354-P | Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology | Kylee Maclachlan | ![]() |
![]() |
|||
355-P | A novel genomewide RNA-Targeting CRISPR/Cas13 Screen Identifies a Plasma Cell-Specific long non-coding RNA (LncRNA) Essential for Myeloma Cell Growth | Domenico Maisano | ![]() |
![]() |
|||
356-P | Effect of Amplification or Gain of 1Q21 in patients with Multiple Myeloma treated with Dartumumab | Irene Zamanillo Herreros | ![]() |
![]() |
|||
357-P | Individualized Risk in Newly Diagnosed Multiple Myeloma | Francesco Maura | ![]() |
![]() |
|||
358-P | Myeloma at a younger age presents with distinctive clinical and molecular features | Mateo Mejía saldarriaga | ![]() |
![]() |
|||
359-P | Non-Paraskeletal Extramedullary Disease Is Associated with high rates of high risk cytogenetic alterations and has a distinct transcriptional profile | Mateo Mejia Saldarriaga | ![]() |
![]() |
|||
371-P | Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition. | Torsten Steinbrunn | ![]() |
![]() |
|||
372-P | Transcriptomic expression of BMP-2, BMP-6 and Smad6 genes in newly diagnosed and relapsed multiple myeloma patients | Panagiotis Stoikos | ![]() |
![]() |
|||
373-P | Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications | Phaik Ju Teoh | ![]() |
![]() |
|||
376-P | Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses | Jing Zhang | ![]() |
![]() |
|||
380-P | Immunological Aging Is Associated with Worse Clinical Outcome in Elderly Newly Diagnosed Multiple Myeloma Patients | Wassilis Bruins | ![]() |
![]() |
|||
381-P | Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients | Lucia Chen | ![]() |
![]() |
|||
382-P | Dysregulations of the immune tumor microenvironment in multiple myeloma | Danka Cholujova | ![]() |
![]() |
|||
385-P | Single cell RNA sequencing reveals activated translation machinery in memory T cells among exceptional responders to lenalidomide | Joselle Cook | ![]() |
![]() |
|||
388-P | An IL-1 driven neutrophil-stromal cell axis fosters a BAFF-rich tumor-supportive bone marrow environment in multiple myeloma patients | Tom Cupedo | ![]() |
![]() |
|||
390-P | The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study | Kane Foster | ![]() |
![]() |
|||
391-P | Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling | Suzanne Lentzsch | ![]() |
![]() |
|||
394-P | Proteomic Analysis to Discover Bone Marrow Plasma Biomarkers Predicting Outcome Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients | Diane Jelinek | ![]() |
![]() |
|||
399-P | Isatuximab Promotes Immune Activation in the Bone Marrow Microenvironment of Patients with High Risk Smoldering Multiple Myeloma | Mario L. Marques-Piubelli | ![]() |
![]() |
|||
400-P | An immune atlas of the dysfunctional cellular and antibody response to COVID-19 vaccination in patients with multiple myeloma | Esperanza Martín-Sánchez | ![]() |
![]() |
|||
406-P | Development of a 3D bioreactor model using a perfusion bioreactor to study osteocyte progenitor cells and the Involvement of single ECM molecules in Multiple Myeloma Bone Disease | Wyonna Darleen Rindt | ![]() |
![]() |
|||
411-P | Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies | Romanos Sklavenitis-Pistofidis | ![]() |
![]() |
|||
413-P | Inflammatory markers characterize neutrophils and C1q TAMs in the day 100 bone marrow aspirate post ASCT of patients with early progression | Caleb Stein | ![]() |
![]() |
|||
420-P | Unusual Presentations of Amyloidosis: A Multicase Analysis Highlighting Diverse Clinical Manifestations and Diagnostic Challenges | Ashwathy Pillai | ![]() |
![]() |
|||
421-P | Reference interval of free light chain ratio for patients on chronic hemodialysis | Pablo Bustamante | ![]() |
![]() |
|||
422-P | Impact of early response and CXCR4 mutation status on progression-free survival with ibrutinib-based therapy in Waldenström macroglobulinemia: A post hoc analysis of the iNNOVATE trial | Colleen McGowan | ![]() |
![]() |
|||
424-P | Partial response or better at 6 months is not shown to be a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with acalabrutinib: A post hoc analysis | Jorge Castillo | ![]() |
![]() |
|||
430-P | INCIDENCE OF PRIMARY PLASMA CELL LEUKEMIA WITH THE NEW DIAGNOSTIC CRITERIA. | Virginia Jano | ![]() |
![]() |
|||
433-P | Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response | Emre Karayol | ![]() |
![]() |
|||
436-P | Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Amyloid Light Chain (AL) Amyloidosis | Paolo Lopedote | ![]() |
![]() |
|||
438-P | Castleman disease: histopathologic reclassification, clinical characteristics and endpoints in a reference center in Mexico | DEBORAH MARTINEZ | ![]() |
![]() |
|||
441-P | Soluble Urokinase Plasminogen Activator Receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study | Agne Paner | ![]() |
![]() |
|||
448-P | Impact of Molecular Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas | udit yadav | ![]() |
![]() |
|||
449-P | Role of Education and Empowerment in Multiple Myeloma patients | Jay Hydren | ![]() |
![]() |
|||
451-P | Association between Dexamethasone Exposure and Visually Significant Cataracts in Myeloma | Rahul Banerjee | ![]() |
![]() |
|||
452-P | Financial Toxicity and Time Toxicity among Patients with Multiple Myeloma | Rahul Banerjee | ![]() |
![]() |
|||
453-P | Randomized Phase II Study of Digital Life Coaching during Stem Cell Transplantation for Myeloma | Rahul Banerjee | ![]() |
![]() |
|||
459-P | A Randomized, Controlled Phase 2 Trial of Uproleselan, an E-Selectin Inhibitor, vs Placebo to Reduce GI Toxicity in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant | Zachary Crees | ![]() |
![]() |
|||
461-P | An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses | Maya Gilbert | ![]() |
![]() |
|||
463-P | Patient Characteristics and Burden in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey | Francesca Gay | ![]() |
![]() |
|||
464-P | Treatment Decision-Making in Patients Diagnosed With Multiple Myeloma | Mary Baugh | ![]() |
![]() |
|||
466-P | PERIPHERAL AND SEVERE AUTONOMIC NEUROPATHY CHARACTERIZED BY DIZZINESS, ORTHOSTATIC HYPOTENSION AND WEIGHT LOSS CAUSED BY BORTEZOMIB. | Danielle Bradshaw | ![]() |
![]() |
|||
467-P | Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse National Health and Nutrition Examination Survey (NHANES) case-control study | Urvi Shah | ![]() |
![]() |
|||
470-P | Single center experience of denosumab for hypercalcemia in multiple myeloma | Matthew Lei | ![]() |
![]() |
|||
473-P | Real-world evidence of Statins and Oral Antidiabetics for Multiple Myeloma | Nieves Lopez-Muñoz | ![]() |
![]() |
|||
476-P | More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial | Elizabeth Moore | ![]() |
![]() |
|||
478-P | Humanistic, Clinical, and Economic Burden in Patients with Relapsed or Refractory Multiple Myeloma on Second Line or Higher Therapy: A Systematic Literature Review | Erin Cook | ![]() |
![]() |
|||
479-P | Disparities in Clinical Trial Enrolment and Survival Outcomes by Socio-economic Class in Multiple Myeloma | Amrutha Sridhar | ![]() |
![]() |
|||
481-P | The effect of touch on pain, anxiety and the patient experience during bone marrow biopsies | Anna Schaal | ![]() |
![]() |
|||
482-P | Dietary habits correlate with myeloma pathogenesis and treatment outcome in multiple myeloma | Lilli Sester | ![]() |
![]() |
|||
483-P | A Whole Foods Plant-based Weight Loss Intervention Improves Metabolic and Immune Biomarkers in MGUS/SMM Patients as well as Progression Trajectory in a Subset The NUTRIVENTION Trial | Urvi Shah | ![]() |
![]() |
|||
484-P | Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias. | Gunjan Shah | ![]() |
![]() |
|||
486-P | Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma | Ram Prakash Thirugnanasambandam | ![]() |
![]() |
|||
487-P | Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with Multiple Myeloma in outpatient care: A longitudinal observational study | Ella Willenbacher | ![]() |
![]() |
|||
488-P | Expert in the Loop - AI assisted generation of Real-World-Evidence | Wolfgang Willenbacher | ![]() |
![]() |
|||
500-P | MULTIPLE MYELOMA: Do we have scales to assess the risk of Thromboembolic Events (TEV)? | Dianis Escorcio | ![]() |
![]() |
|||
504-P | A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) | Betsy ODonnell | ![]() |
![]() |
September 27 - 30, 2023 Athens
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|